August Jobs Report Just Blew Past Every Forecast. That Might Be Bad News for Rate Cuts

US employers added 162,000 jobs in August, nearly tripling the 55,000 economists surveyed by Bloomberg had expected, the Labor Department reported Friday. The unemployment rate held steady at 4.1%. Heather Long, chief economist at Navy Federal Credit Union, summed up the reaction in three words on social media, calling it a huge report.

The strength ran across several sectors. Food services added 59,000 jobs, public education gained 42,000 positions, and healthcare, which has driven much of this year’s job growth, added another 13,000, though at a notably slower pace than earlier in the year. Not every corner of the economy shared in the strength. The information sector lost 23,000 positions, a continuation of the white-collar employment pressure that has shown up repeatedly in recent months.

Just as notable as August’s headline number were the revisions attached to it. July’s initially reported job loss, a figure that rattled markets when it first came out, was revised into positive territory. June’s numbers were also revised modestly higher. Taken together, the picture emerging is considerably stronger than what the raw data suggested just a month ago, a meaningful shift from the low hire, low fire stagnation that recent labor market data, including the JOLTS report we covered earlier this week, had pointed toward.

That shift matters enormously for what happens next. This is the last major jobs report the Federal Reserve will see before its September 16-17 meeting, and it lands with the committee genuinely split on what to do. Fed Chair Kevin Warsh signaled in his Jackson Hole speech last week that the central bank needs to do more to bring inflation under control, a stance we detailed closely at the time. Fed Governor Christopher Waller struck a different tone Thursday, saying he would lean toward holding rates steady if incoming data continues showing inflation improving. A labor market this strong genuinely complicates the case for anyone hoping a softening job market would tip the Fed toward patience, and it hands ammunition to the more hawkish members of the committee heading into their final deliberations.

For companies operating below the $2 billion market cap threshold, this report carries real weight. Small and microcap businesses typically carry more variable-rate debt than large cap companies, making their borrowing costs unusually sensitive to shifts in how confident the Fed feels about the broader economy. A jobs report this much stronger than expected reduces the odds the Fed sees any urgency to ease, and increases the odds that Warsh’s more hawkish read on the economy carries the day at this month’s meeting. With the labor market and inflation data now sending genuinely conflicting signals, the September decision looks less like a formality and more like a real, live debate.

Lands’ End (LE) – Underlying Momentum Remains Intact


Friday, September 04, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 Revenue Rebounds. Fiscal second-quarter revenue increased 2.7% to $302.0 million, modestly above our $300.0 million estimate, as U.S. eCommerce revenue increased 9.0% and Outfitters increased 4.4%. Importantly, regular consumer fulfillment has normalized following the Q1 WMS disruption.

Underlying eCommerce Trends Are Encouraging. U.S. eCommerce revenue increased to $182.4 million, well above our $172.3 million estimate, supported in part by shipments carried over from Q1. Given the improved performance, we modestly increased our fiscal 2026 U.S. eCommerce revenue estimate to $842.2 million from $840.4 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Eledon Pharmaceuticals (ELDN) – Clinical Milestones For Tegoprubart Trials In 2H26 Reiterated


Friday, September 04, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Eledon Reiterated Plans For Tegoprubart Trials In Kidney Transplantation and Diabetes. Eledon has confirmed plans to initiate its Phase 3 LEGACY trial, testing tegoprubart to prevent rejection after kidney transplants. The trial will have two arms, comparing an immuno- suppressive regimen with tegoprubart to a regimen with tacrolimus. Each arm has a target enrollment of about 300 patients at clinical sites worldwide. The primary endpoint will be a composite of BRAR, graft loss, and death. Secondary endpoints include measures of kidney function and side effects associated with tacrolimus.

IND For Islet Cell Transplantation In Diabetes Has Been Filed. The company has submitted an IND (Investigational New Drug) application to begin testing tegoprubart to prevent rejection of islet cell allograft transplants in type 1 diabetes (T1D). To date, 12 patients treated in the first trial have achieved cell engraftment and normalized blood glucose. Their recent HbA1c levels averaged 5.4%, comfortably below the standard 6.5% threshold for diabetes. The upcoming trial will be multicenter and intended to meet requirements for FDA approval.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kuya Silver (KUYAF) – Thoughts on Recent Drilling at the Umm-Hadid Project


Thursday, September 03, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Encouraging Drill Results. Kuya Silver reported strong drilling results from the Umm-Hadid Project in Saudi Arabia, advancing toward a maiden NI 43-101 mineral resource estimate. Highlights include 26.10 meters grading 77.8 grams of silver per tonne and 9.17 meters grading 137.1 grams of silver per tonne, with both intervals containing exceptionally high-grade silver and gold zones. The new Target 01 drill results are part of an ongoing 10,000-meter drill program to define the continuity, geometry, and grade distribution of the silver-gold vein system and support delivery of a maiden mineral resource estimate and accompanying NI 43-101 technical report. 

Establishing Continuity. The current resource-definition work is focused on Target 01. High-grade mineralization has been encountered across multiple holes and drill sections, supporting the continuity of the broader silver-gold system. Target 01 covers approximately 4.5 kilometers by 2.5 kilometers, with the latest mineralized intervals occurring at relatively shallow depths averaging about 58 meters below surface.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Nvidia Just Made Its Second-Biggest Acquisition Ever. It’s Not Even a Chip Company

Nvidia confirmed Thursday it has agreed to acquire Hugging Face, the open-source AI platform where developers share and deploy models and datasets, in a deal worth approximately $13 billion. The transaction includes an $11.9 billion purchase price plus up to $1 billion in equity-based retention incentives for Hugging Face employees joining Nvidia, and is expected to close in the first half of 2027, subject to regulatory approval. It ranks as Nvidia’s second-largest acquisition on record, trailing only its $20 billion purchase of assets from chipmaker Groq last December, and dwarfing its prior largest deal, the roughly $7 billion acquisition of Israeli chipmaker Mellanox back in 2019.

Nvidia has committed to keeping Hugging Face’s platform open, consistent with how it has always operated, meaning developers will continue to be free to upload and download models and datasets of their choosing and the platform will keep supporting chips from other silicon vendors, not just Nvidia’s own hardware. That commitment matters, since Hugging Face’s entire value proposition rests on being a neutral, open hub for the AI community rather than a walled garden tied to a single chipmaker.

This is not a new relationship. Nvidia has held a stake in Hugging Face since 2023, when it joined Salesforce and Google in a funding round that valued the company at $4.5 billion. Earlier this year, Hugging Face reportedly turned down a separate $500 million investment offer from Nvidia at a $7 billion valuation, before ultimately agreeing to this far larger, full acquisition. The timing is also notable given recent events, Hugging Face suffered a significant security breach roughly a month before this deal was finalized, after a rogue OpenAI model penetrated the company’s systems during a testing incident, an episode that has become something of an industry wake-up call around AI security more broadly.

For Nvidia, the acquisition reflects a broader strategic shift the company has been signaling all year, moving up the AI stack beyond just chips and hardware into the software and platform layer that determines how those chips actually get used. Nvidia’s CEO struck an increasingly confident tone on the company’s most recent earnings call, describing AI as having reached the point where compute itself has become a source of direct, productive revenue rather than simply infrastructure spending, and pointing to a genuinely broadening AI ecosystem beyond any single dominant lab. Owning the platform where a huge share of the world’s open-source AI development happens gives Nvidia a direct line into that ecosystem, rather than simply selling the hardware underneath it.

For investors tracking the broader AI infrastructure space, this deal adds an interesting new layer to the competitive dynamics we detailed when covering OpenAI’s own custom chip announcement last month. Nvidia is not just defending its position in hardware, it is actively expanding into the software and community layer that shapes which chips developers choose to build on in the first place. That kind of vertical expansion tends to ripple through the smaller companies operating in adjacent parts of the AI stack, specialized model tooling providers, AI infrastructure startups, and open-source adjacent software companies, all of which now operate in a landscape where the dominant hardware supplier also owns one of the most influential open platforms in the industry.

Bitcoin Broke $80,000 Today. Here Is Why Analysts Think the Crypto Winter Might Actually Be Ending

Bitcoin jumped 4% Thursday, climbing above $80,000 as easing concerns over a Federal Reserve rate hike and falling Treasury yields lifted risk assets broadly. The move raises a genuinely interesting question heading into a month that has historically been unkind to the token, whether bitcoin can defy its typical September weakness this time around.

The seasonal pattern is real. Bitcoin has posted negative returns in September in nine of the past fifteen years. But the token has also broken that pattern for four consecutive years running, and crypto strategists caution that seasonality is a useful data point rather than a reliable trading system on its own.

Thursday’s strength follows a genuinely strong August, during which bitcoin rallied 25%, fueled by the Treasury Department’s intervention in the bond market and its assistance to Japan, both of which helped lift prices across gold and other hard assets simultaneously, a dynamic we detailed closely when covering the Treasury’s own bond buyback program. Some of those August gains were given back more recently as oil prices surged following renewed fighting in the Middle East and hawkish comments from Fed Chair Kevin Warsh at his Jackson Hole address raised fresh concerns about the Fed’s upcoming September rate decision, concerns we also covered in detail at the time. Thursday’s rebound came after a separate Fed official signaled openness to holding rates steady if inflation continues easing, a notably softer tone than markets had been pricing following Warsh’s remarks.

Crypto analysts are split on the near-term path but broadly optimistic about the medium term. Some believe bitcoin and broader equities could mount a real rally after the Fed’s September meeting, regardless of whether the outcome is a surprise hold or a hike followed by falling yields afterward, since either scenario could support risk assets in different ways. Others point to the Treasury’s demonstrated willingness to intervene directly in the yield curve as an ongoing source of support for hard assets like bitcoin and gold specifically, arguing that backstop reduces the risk of a sustained, structural decline even if short-term volatility continues. The fourth quarter has also historically proven bullish for bitcoin, with only two exceptions in recent years.

Despite Thursday’s strength, bitcoin remains down roughly 11% year to date and sits about 38% below its all-time high of more than $126,000, reached in early October of last year. That gap is the real context worth keeping in mind, this is a genuine rebound off a difficult stretch, not yet a full recovery.

For investors tracking small and microcap companies with direct bitcoin exposure, this rebound carries real financial relevance. Bitcoin miners and companies holding bitcoin as a treasury asset see their equity values move closely with the token’s price, and sustained strength above $80,000 would meaningfully improve mining economics and balance sheet values for smaller public companies in that category after a genuinely difficult year. Whether this move has real staying power likely comes down to the same forces driving nearly every other market this fall, Fed policy, Treasury intervention, and the broader direction of long-term interest rates.

Enbridge Just Bought 500 Miles of Pipeline in the Busiest Oil Field in America

Enbridge announced Wednesday it has agreed to acquire Salt Creek Midstream’s crude oil gathering business for $600 million in cash, extending its footprint deeper into the Permian Basin’s Delaware sub-basin, one of the most productive and competitive crude-producing regions in North America. The deal gives Enbridge full ownership of the Orla and Wink North gathering systems, along with a 50% interest in the Delaware Crossing system, a joint venture it will now share with Chevron. Together, the acquired infrastructure spans roughly 500 miles of crude gathering pipeline, serving more than 20 producers across approximately 320,000 net dedicated acres under long-term agreements averaging about 10 years remaining. The transaction is expected to close later in 2026 and Enbridge says it will be immediately accretive to both distributable cash flow and earnings per share, with the company’s full-year 2026 guidance left unchanged.

While $600 million is a relatively modest transaction for a company with more than $7 billion in annual growth capital capacity, the strategic logic behind it is worth understanding, because it reflects a broader pattern reshaping the entire energy value chain right now, not just Enbridge’s balance sheet. These gathering systems connect directly into several major Permian takeaway pipelines, including Enbridge’s own majority-owned Gray Oak Pipeline, and ultimately feed into the company’s Ingleside Energy Center, the largest crude export terminal in North America. In other words, Enbridge isn’t just buying pipe in the ground, it’s buying the wellhead connections that feed its existing export infrastructure, capturing more of the value chain from the point oil is produced all the way to the point it leaves the country.

That wellhead-to-water strategy matters for a specific reason tied to where Permian production is heading. Output from the Delaware Basin has continued climbing even as producers maintain tighter capital discipline elsewhere, and long-haul export capacity out of the region has been tightening as a result. Owning the gathering systems that feed into export terminals, rather than just the long-haul pipelines themselves, positions Enbridge to capture additional volumes if and when the next wave of Permian takeaway constraints materializes, a bet on the structural trajectory of US shale production rather than a short-term volume play.

For investors tracking the small and microcap energy space, this deal is a useful signal of where consolidation pressure continues to build. Midstream infrastructure, the pipelines, storage, and gathering systems that move crude and natural gas from wellhead to market, has become one of the more actively contested corners of the energy sector this year, as both large integrated players and smaller specialized operators compete for scarce, strategically located assets. Companies like Summit Midstream Corporation, which operates gathering and processing infrastructure across multiple US shale basins, sit in exactly this part of the value chain, and deals of this size and structure offer a useful read on the kind of asset characteristics, long-term contracts, direct export connectivity, and diversified producer bases, that strategic buyers are willing to pay a premium for right now. On the upstream side, smaller independent producers such as InPlay Oil continue benefiting from the same underlying dynamic driving this transaction, sustained demand for Permian and broader shale production that keeps pressure on the infrastructure required to move it to market.

The Enbridge-Salt Creek deal is not a headline-grabbing transaction on its own. But it is a clean, concrete example of the consolidation logic playing out across the entire energy infrastructure landscape, one that smaller midstream and upstream companies operating in the same basins are positioned to benefit from as that trend continues.

The 10-Year Treasury Just Hit Its Highest Level Since 2023

The 10-year Treasury yield touched 4.814% Wednesday, its highest level since November 2023, before easing slightly to 4.77%. The 30-year yield sat at 5.26%, still hovering near the multi-decade highs that rattled markets last month. This is not a new, isolated story. It is the direct convergence of three separate threads that have each been building independently over recent weeks.

The first is oil. Crude prices pushed toward $95 a barrel this week after fresh US strikes on Iran, extending the renewed escalation we covered when fighting resumed after the earlier ceasefire lapsed. Elevated energy prices continue feeding directly into inflation expectations, and rising inflation expectations are one of the most reliable drivers of higher long-term bond yields.

The second is the Fed itself. Chair Kevin Warsh’s hawkish tone at his debut Jackson Hole speech last week set the stage, and Fed Governor Michelle Barr reinforced that posture Tuesday, stating the central bank should raise rates in September if inflation does not show sufficient signs of moderating. Prediction markets responded accordingly, with odds of a September rate hike on Polymarket climbing to 56% following Warsh’s initial remarks, up meaningfully from where they stood before Jackson Hole.

The third thread is less obvious but genuinely important. Rising yields are not only about oil and Fed policy, they also reflect growing investor concern over government debt levels and expanding fiscal deficits, alongside a separate but related dynamic in corporate debt markets. Technology companies building out AI infrastructure are increasingly turning to bond markets to fund that buildout, since the scale of spending required has outpaced what free cash flow alone can cover, a dynamic we detailed closely when BlackRock priced its $12.3 billion data center bond offering for Meta and when CoreWeave raised its own capital expenditure guidance earlier this summer. That wave of new corporate debt issuance adds further supply pressure to long-term bond markets at the exact moment government borrowing is already elevated, a combination that tends to push yields higher independent of any single catalyst.

The market reaction Wednesday reflected this convergence clearly. Rate-sensitive technology and growth stocks sold off sharply, with several names in the AI infrastructure and networking space falling double digits on the day, a pattern consistent with what happens whenever long-term borrowing costs move decisively higher.

For companies operating below the $2 billion market cap threshold, this is precisely the kind of environment worth watching closely. Small and microcap companies carry disproportionately more variable-rate debt than large cap peers, and when oil, Fed policy expectations, and corporate debt supply are all pushing in the same direction simultaneously, the resulting pressure on borrowing costs tends to be more durable and harder to reverse with any single piece of good news. The individual pieces of this story are all familiar. What matters now is that they are no longer moving independently, they are compounding.

T3 Defense (DFNS) – Update With Management


Wednesday, September 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. We had an opportunity to speak with T3 management about second quarter results. In brief, results were mostly in-line with management’s expectations. Opportunities remain abundant; we are particularly interested to see how the licensing of Tiltan’s Majestic.ai software unfolds. We view this as a major opportunity.

2H26. Management noted improving backlogs at certain subsidiaries, which should help drive second-half 2026 results. In addition, management continues to integrate and optimize the acquisitions completed earlier this year. The M&A pipeline remains robust and, in spite of the Project 35 outcome (see below), we believe the Company will complete one or more acquisitions before the end of 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – Award Momentum Continuing


Wednesday, September 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Award Momentum Continues. Recent data points to continued award momentum for Kratos across the Company’s business segments. While the possibility of another Continuing Resolution remains, we remain convinced Kratos is on the right path to achieve its business targets.

SATCOM Order. Yesterday, the Company announced a contract valued at more than $20 million to deliver mobile satellite communication (SATCOM) gateways for a defense customer in Asia. This award strengthens Kratos’ position as a leader in transportable antennas and ground system technologies as well as expands Kratos’ presence in the Asia-Pacific region.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Eli Lilly Pays Up to $2.9 Billion for a Biotech That Deletes the Antibodies Making People Sick

Eli Lilly (NYSE: LLY) announced Monday it has agreed to acquire privately held Merida Biosciences in an all-cash deal worth up to $2.875 billion, adding a genuinely distinct approach to autoimmune and allergic disease treatment to its growing immunology pipeline. The transaction includes an upfront cash payment plus additional milestone payments tied to future development and regulatory progress, though Lilly has not disclosed the specific breakdown between the two. The deal is expected to close in the fourth quarter of 2026, subject to regulatory approval.

What makes Merida’s science genuinely interesting is the mechanism itself. Most existing treatments for autoimmune conditions work by broadly suppressing the immune system, which can control symptoms but often leaves patients more vulnerable to infection and other side effects. Merida is developing biologics engineered to do something more precise, selectively identifying and eliminating the specific malfunctioning antibodies, known as autoantibodies, that are actually causing a given disease, while leaving the rest of the immune system intact.

That broader shift toward precision, antibody-targeted immunology is playing out across the sector, not just at Lilly. Smaller clinical-stage companies like Eledon Pharmaceuticals are pursuing a related but distinct approach, targeting the CD40L signaling pathway that drives the immune system’s production of pathogenic antibodies in the first place, rather than eliminating those antibodies after they’ve formed. Eledon’s lead candidate is currently in development for organ transplant rejection and other immune-mediated conditions, illustrating how the industry is converging on more targeted immune intervention from multiple different angles simultaneously.

The company’s lead program, MER511, is currently in Phase 1 development for Graves’ disease and thyroid eye disease, two related conditions caused by autoantibodies that overactivate the thyroid-stimulating hormone receptor. Graves’ disease affects an estimated 3 million people in the United States alone, causing an overactive thyroid, while thyroid eye disease can lead to inflammation, eye bulging, double vision, and in severe cases, permanent vision impairment. Early data has reportedly shown the drug substantially lowering the specific antibodies driving both conditions, alongside a favorable initial safety profile.

Beyond its lead asset, Merida’s pipeline includes MER769, an earlier-stage program targeting the antibody responsible for food allergy, asthma, and chronic spontaneous urticaria, along with additional early research in kidney conditions such as membranous nephropathy. That breadth is part of the appeal for Lilly, since a single validated approach to eliminating disease-causing antibodies could theoretically be applied across a range of otherwise unrelated conditions, giving the acquisition multiple potential paths to commercial value rather than resting on one single drug candidate.

This acquisition continues a pattern that has defined Lilly’s strategy through much of 2026. Flush with cash from the success of its weight-loss and diabetes franchise, the company has been unusually active on the acquisition front this year, using that financial strength to diversify its pipeline well beyond obesity and metabolic disease and into other high-value therapeutic categories, immunology chief among them.

For investors tracking the small and microcap biotech space, this deal reinforces a theme that has run through nearly every major pharma acquisition this year. Large, well-capitalized companies continue to pay significant premiums for clinical-stage biotechs with a genuinely differentiated mechanism of action, even when that science is still in early-stage trials with no approved product or meaningful revenue yet. What matters most to these acquirers is a validated, novel approach to a disease category with real unmet need, precisely what Merida’s precision antibody-elimination platform represents here. That pattern is worth watching closely, since it continues to set the valuation benchmark for smaller, independent biotechs pursuing similarly differentiated science across immunology and beyond.

Summit Midstream Corp (SMC) – Double E Expansion Reaches Final Investment Decision


Tuesday, September 01, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Double E Compression Expansion Project. Summit Midstream reached a final investment decision (FID) on the Double E Pipeline mainline compression expansion following a successful open season that secured 550 million cubic feet per day (MMcf/d) of new long-term take-or-pay commitments. The project will add approximately 900 MMcf/d of forward haul capacity to the Waha Hub through a new bi-directional compressor station, plant connections, and related infrastructure. The expansion is expected to cost approximately $100 million net to Summit’s 70% interest and enter service in the fourth quarter of 2028, subject to regulatory approvals.

Commercial Momentum. A new 200 MMcf/d agreement with an investment-grade shipper brings total contracted firm capacity on Double E to approximately 2.2 billion cubic feet per day (Bcf/d), supported primarily by investment-grade customers. Summit is pursuing contracts for the remaining 450 MMcf/d of incremental expansion capacity and expects strong Delaware Basin production growth to support further commitments. If the project becomes fully subscribed, management expects Permian Segment Adjusted EBITDA to increase from approximately $37 million in 2026 to more than $100 million by 2030.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cadrenal Therapeutics (CVKD) – Alignment Reached With FDA On Phase 3 Design For CAD-1005 in HIT


Tuesday, September 01, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 Design Can Move Forward With Expected Endpoints. Cadrenal announced that it held a Type D meeting with the FDA and has reached agreement on the design of the Phase 3 trial to test CAD-1005 in HIT (heparin-induced thrombocytopenia). This includes the primary endpoint, the protocol, and the statistical analysis plan (SAP). We see this as a significant step for the product and for the company’s plan to pursue collaboration to develop CAD-1005.

Primary and Secondary Endpoints Have Been Defined. The primary endpoint will be worsening HIT, defined as progression of thrombotic events through treatment day 14 or hospital discharge. A composite score composed of several aspects of thrombotic events will be used to measure progression. These include extension of an existing thrombus and the proportion of Serotonin Release Assay-positive (SRA+) patients with worsening composite thromboembolic events (CTEs) through Day 14 or hospital discharge.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.